Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors - PubMed
5 hours ago
- #immunotherapy
- #cancer research
- #clinical trial
- INBRX-105 is a tetravalent, PD-L1-targeted TNFRSF9 (4-1BB) agonist evaluated in a phase 1 study for solid tumors.
- The study included 160 patients, with 81 receiving monotherapy and 79 receiving combination therapy with pembrolizumab.
- The maximum tolerated dose of INBRX-105 was 0.3 mg/kg every 3 weeks.
- Common adverse events included fatigue, increased aspartate aminotransferase, and nausea, with notable hepatic toxicity.
- Objective response rates were low: 8.8% overall, 3.7% for monotherapy, and 13.9% for combination therapy.
- Clinical development of INBRX-105 was discontinued due to hepatotoxicity and limited efficacy.
- The study highlights the need for novel immunotherapy combinations to address tumor resistance to checkpoint inhibitors.